Search research articles
Contact Us
Filters
Showing results (321-330 of 343) with videos related to
Page
of 35
Sort By:
American Journal of Hematology
|
January 2, 2023
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study
Brian T Hess, Anshu Giri, Yeonhee Park, et al.
JCO Global Oncology
|
August 8, 2022
Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study
Eloísa Riva, Patricio José Duarte, Bryan Valcárcel, et al.
Blood Advances
|
June 5, 2025
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia
Andrew R Branagan, Clifton Mo, Matthew Lei, et al.
Leukemia & Lymphoma
|
July 3, 2018
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients
Artur Jurczyszyn, Jorge J Castillo, Irit Avivi, et al.
British Journal of Haematology
|
January 10, 2018
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients
Artur Jurczyszyn, Jakub Radocha, Julio Davila, et al.
Blood Advances
|
December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial
Meletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 11, 2023
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Blood
|
July 31, 2020
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study
Constantine S Tam, Stephen Opat, Shirley D'Sa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
Meletios A Dimopoulos, Stephen Opat, Shirley D'Sa, et al.
American Journal of Hematology
|
April 7, 2017
IgM myeloma: A multicenter retrospective study of 134 patients
Jorge J Castillo, Artur Jurczyszyn, Lucie Brozova, et al.
Page
of 35
Search research articles
Search
Showing results (321-330 of 343) with videos related to
Sort By:
Page
of 35
American Journal of Hematology
|
January 2, 2023
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study
Brian T Hess, Anshu Giri, Yeonhee Park, et al.
JCO Global Oncology
|
August 8, 2022
Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study
Eloísa Riva, Patricio José Duarte, Bryan Valcárcel, et al.
Blood Advances
|
June 5, 2025
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia
Andrew R Branagan, Clifton Mo, Matthew Lei, et al.
Leukemia & Lymphoma
|
July 3, 2018
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients
Artur Jurczyszyn, Jorge J Castillo, Irit Avivi, et al.
British Journal of Haematology
|
January 10, 2018
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients
Artur Jurczyszyn, Jakub Radocha, Julio Davila, et al.
Blood Advances
|
December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial
Meletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 11, 2023
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Blood
|
July 31, 2020
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study
Constantine S Tam, Stephen Opat, Shirley D'Sa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
Meletios A Dimopoulos, Stephen Opat, Shirley D'Sa, et al.
American Journal of Hematology
|
April 7, 2017
IgM myeloma: A multicenter retrospective study of 134 patients
Jorge J Castillo, Artur Jurczyszyn, Lucie Brozova, et al.
Page
of 35